Article:Severe localised granulomatosis with polyangiitis (Wegener's granulomatosis) manifesting with extensive cranial nerve palsies and cranial diabetes insipidus: a case report and literature review. (5930853)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at https://www.wikidata.org/wiki/Q55286318. Its title is Severe localised granulomatosis with polyangiitis (Wegener's granulomatosis) manifesting with extensive cranial nerve palsies and cranial diabetes insipidus: a case report and literature review. and the publication date was 2018-05-01. The initial author is James E. Peters.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.



Converted JATS paper:

Journal Information

Title: BMC Neurology

Severe localised granulomatosis with polyangiitis (Wegener’s granulomatosis) manifesting with extensive cranial nerve palsies and cranial diabetes insipidus: a case report and literature review

  • James E. Peters
  • Vivek Gupta
  • Ibtisam T. Saeed
  • Curtis Offiah
  • Ali S. M. Jawad

Publication date (epub): 5/2018

Publication date (pmc-release): 5/2018

Publication date (collection): /2018

Abstract

Background

Granulomatosis with polyangiitis (GPA, formerly Wegener’s granulomatosis) is a multisystem vasculitis of small- to medium-sized blood vessels. Cranial involvement can result in cranial nerve palsies and, rarely, pituitary infiltration.

Case presentation

We describe the case of a 32 year-old woman with limited but severe GPA manifesting as progressive cranial nerve palsies and pituitary dysfunction. Our patient initially presented with localised ENT involvement, but despite treatment with methotrexate, she deteriorated. Granulomatous inflammatory tissue around the skull base resulted in cavernous sinus syndrome, facial nerve palsy, palsies of cranial nerves IX-XII (Collet-Sicard syndrome), and the rare complication of cranial diabetes insipidus due to pituitary infiltration. The glossopharyngeal, vagus and accessory nerve palsies resulted in severe dysphagia and she required nasogastric tube feeding. Her neurological deficits substantially improved with treatment including high dose corticosteroid, cyclophosphamide and rituximab.

Conclusions

This case emphasises that serious morbidity can arise from localised cranial Wegener’s granulomatosis in the absence of systemic disease. In such cases intensive induction immunosuppression is required. Analysis of previously reported cases of pituitary involvement in GPA reveals that this rare complication predominantly affects female patients.  

Paper

Background

Granulomatosis with polyangiitis (GPA, formerly Wegener’s granulomatosis) is an autoimmune vasculitis of small- to medium-sized blood vessels. The Chapel Hill 2012 Consensus Criteria define GPA as “necrotizing granulomatous inflammation usually involving the upper and lower respiratory tract and necrotizing vasculitis affecting predominantly small to medium vessels” [[1]]. In their seminal 1954 review, Godman and Churg recognized that Wegener’s granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome shared certain clinico-pathological features, and comprised a subset of vasculitides distinct from ‘periarteritis nodosa’ (now polyarteritis nodosa) [[2]]. The discovery that anti-neutrophil cytoplasmic antibodies (ANCA) are present in over 90% of patients with GPA and microscopic polyangiitis, and approximately 30% of those with Churg-Strauss syndrome has led to these three clinical syndromes being classified under the umbrella term ‘ANCA-associated vasculitis’. Patients with GPA typically show a cytoplasmic pattern of ANCA staining on indirect immunofluorescence (‘cANCA pattern’), with antibodies directed against proteinase-3 (PR3), a neutrophil protease.

The generalised form of GPA described by Wegener is characterized histopathologically by the triad of necrotizing vasculitis, pauci-immune focal necrotizing glomerulonephritis and necrotizing granulomatous inflammation of the respiratory tract. This systemic form of the disease can be life-threatening, particularly in the presence of pulmonary haemorrhage or rapidly progressive crescenteric glomerulonephritis. Prior to the introduction of cyclophosphamide [[3]], mortality was over 80% [[4]]. Modern treatment involves intensive immunosuppressive therapy with high dose corticosteroids and cyclophosphamide or rituximab to induce remission [[5], [6]]. Once remission is achieved, patients are switched to less toxic maintenance immunosuppression, such as azathioprine and low dose glucocorticosteroid.

A limited form of Wegener’s granulomatosis, with lesions localised to the lung, was later identified [[7]]. Patients with limited (now generally referred to as ‘localised’) disease are more likely to be young, female and ANCA negative than those with generalised GPA [[8]]. Localised GPA typically manifests with middle ear and respiratory tract features such as otitis media, sinusitis, nasal collapse and airway stenosis [[8], [9]].

Here we describe a patient with localised but severe granulomatosis with polyangiitis (Wegener’s granulomatosis) manifesting with progressive cranial nerve palsies and pituitary dysfunction. This case emphasises that localised cranial Wegener’s granulomatosis can result in serious morbidity in the absence of systemic disease. In such cases intensive induction immunosuppression is required.

Case presentation

Our patient, a white British female, presented at the age of 32 years with epistaxis, nasal congestion, recurrent bilateral otitis media and progressive hearing loss to an Ear, Nose and Throat (ENT) clinic at her local hospital. A year prior to this she had been fitted with bilateral hearing aids for hearing loss of unknown cause. She subsequently developed a left lower motor neurone facial palsy. A computed tomography (CT) scan showed a left nasopharyngeal mass and inflammatory changes in the middle ear and mastoid air cells. Nasolaryngoscopy revealed inflammation and ulceration of the left nasal turbinate, septum and posterior pharyngeal wall. She had never used cocaine. She underwent an exploratory mastoidectomy with grommet insertion.

Biopsies of the right and left nasopharynx, left middle meatus and septum revealed florid acute and chronic inflammation with mucosal ulceration and extensive necrosis of stroma and cartilage. The inflammatory infiltrate consisted of neutrophils, lymphocytes, and plasma cells, with zones of histiocytes representing granulomata (Fig. 1). Large numbers of multinucleated giant cells were present. Eosinophils were inconspicuous. Histological assessment of vasculitis was difficult due to the extensive necrosis and marked tissue inflammation, but necrotizing vasculitis of small vessels was evident. There was no evidence of malignancy, and stains for fungi and mycobacteria were negative.Fig. 1

Histopathology. Nasal biopsy. H&E stain, magnification X100. Vertical arrows show granuloma. Horizontal left facing arrow: necrosis. Horizontal right facing arrow: angiitis with necrosis in vessel wall.

Anti-neutrophil cytoplasmic antibody (ANCA) testing was positive by immunofluorescence with a cytoplasmic staining pattern. Anti-proteinase-3 (PR3) antibodies measured by enzyme-linked immunosorbent assay (ELISA) were mildly elevated (5.8, normal range < 2). Anti-myeloperoxidase (MPO) antibodies were not detected. CT thorax revealed no pulmonary abnormality and no lymphadenopathy. Serum calcium and angiotensin-converting enzyme (ACE) were normal.

On the basis of the clinico-pathological findings, she was diagnosed with localised granulomatosis with polyangiitis (GPA, formerly known as Wegener’s granulomatosis). Detailed work-up revealed no evidence of pulmonary, renal or other systemic features. She was treated with methotrexate 25 mg weekly and prednisolone 60 mg daily. The prednisolone was weaned to 10 mg over a period of 6 months. As the steroid dose was reduced she deteriorated. She developed headaches, nausea, diplopia, dysphonia and progressive dysphagia to both solids and liquids, resulting in weight loss of 3 stone.

She was referred to our institution by her general practitioner approximately 1 year after her initial presentation. Physical examination revealed left ptosis, a dilated and unreactive left pupil, paresis of left eye movements consistent with palsies of cranial nerves III, IV and VI, a left lower motor neurone facial palsy, and deviation of the tongue to the right. There was wasting of the right sternocleidomastoid. Laryngoscopy revealed a right-sided vocal cord palsy. Blood tests showed mild elevation of the inflammatory markers; the erythrocyte sedimentation rate (ESR) was 34 mm/hour, and the C-reactive protein (CRP) was 26 mg/L. Renal function, urinalysis and urine microscopy were normal. Repeat ANCA testing revealed cytoplasmic pattern ANCA staining, but antibodies to PR3 and MPO were negative.

A contrast-enhanced CT scan of her head and neck (Fig. 2) demonstrated predominantly dural-based enhancing soft tissue abnormality affecting the central skull base. This chronic inflammatory tissue involved the sella turcica (with resultant erosion of the floor of the sella turcica) and both cavernous sinuses. There was associated abnormality involving the pituitary parenchyma, the pituitary stalk and the hypothalamus. Contiguous chronic inflammatory infiltrative changes were also evident in the orbital apices, the petrous temporal bones encasing the carotid canals and the extra-cranial infratemporal fossae including the pterygopalatine fossae. As a result of the cavernous sinus, petrous temporal bone and infratemporal fossae involvement, both internal carotid arteries were occluded in their skull base carotid canal segments, with the anterior circulation sustained through collateral vessels. The sinonasal region demonstrated chronic inflammatory features, with mucosal and submucosal fibrosis and ulceration. Bilateral chronic middle ear and mastoid inflammatory changes were evident. Radiological features of right Collet-Sicard syndrome (palsy of cranial nerves IX-XII) were also present. The appearances, particularly in relation to the skull base infiltration, had progressed significantly compared to 6 months earlier. Her pituitary hormone profile showed elevated prolactin (1353 munit/L; upper limit of normal range = 496) and reduced thyroid-stimulating hormone (TSH) (0.23 munit/L) with normal free thyroxine. On further enquiry, she reported amenorrhoea for the past year.Fig. 2

Coronal contrast-enhanced CT image of the skull base and neck (pre-cyclophosphamide treatment). There is marked abnormal chronic inflammatory infiltration of the cavernous sinuses bilaterally (bold white arrow) and hypophyseal involvement (black arrow). Multiple lower cranial nerve palsies (Collet-Sicard syndrome) as a result of the skull base inflammatory involvement were evident on imaging, including right vocal cord palsy indicated by adducted right true vocal cord and enlarged right laryngeal ventricle (long white arrow)

She had not yet had any children and was keen to do this in the future. We therefore initially opted for treatment with rituximab over cyclophosphamide. She received Rituximab 1 g, with a plan for a second dose two weeks later. Methotrexate was replaced with Azathioprine. She also received one pulse of intravenous (i.v.) methyl prednisolone 500 mg, and her oral prednisolone was increased from 10 mg to 30 mg. Given her modest baseline immunosuppressive treatment, and because of the insidious presentation and lack of systemic features, at the time we felt this mid-range prednisolone dose rather than 1 mg/kg was reasonable. Her CRP fell to 6 mg/L and she was discharged from hospital.

She was seen as an emergency 10 days later. She had developed complete dysphagia to solids and liquids and was unable to manage even small sips of water. Both pupils were now dilated and reacted sluggishly to light, and she had a new right-sided ptosis, indicating a new right-sided third nerve palsy. She also had a new right-sided sixth nerve palsy. Assessment of her swallowing showed that she was aspirating and had an ineffective cough reflex. She was kept nil-by-mouth, and fed through a nasogastric tube. The safety of her airway was assessed by the anaesthetic and ENT teams because of concern that she was at high risk of life-threatening airway obstruction or aspiration should the vocal cord palsies become bilateral. Her CRP had risen to 33 mg/L.

A cranial magnetic resonance imaging (MRI) scan (Figs. 3 and 4a) confirmed the CT findings, and provided greater imaging sensitivity and specificity regarding the extent and severity of the osseus skull base infiltrative changes, the intracranial dural-based disease burden, and the cranial nerve palsies. Muscle atrophy due to denervation as a result of the latter was particularly well demonstrated. In addition, the MRI provided greater detail on the degree of hypothalamic-pituitary axis involvement, and allowed for subsequent imaging assessment of response to treatment.Fig. 3

Coronal T2-weighted MRI image of the skull base and neck (pre-cyclophosphamide treatment). There is severe chronic inflammatory soft tissue abnormality affecting the cavernous sinuses and central and lateral skull base, including the left cavernous sinus and right sphenoid bone and foramen rotundum (large black arrows). Secondary cranial nerve palsies are present. Palsy of the mandibular division of the right trigeminal nerve has resulted in atrophy of the right masticator space muscle, in comparison to the more normal muscle volume on the left (short white arrows). Lower cranial nerve palsies are demonstrated by atrophy of the right superior pharyngeal constrictor muscle (short black arrow) and sternocleidomastoid muscles (long white arrows)

Fig. 4

MR images of the brainstem, skull base and pituitary gland. (a) Coronal contrast-enhanced fat-saturated T1-weighted image of the central skull base demonstrates pathological enhancement of the cavernous sinus, pituitary gland and pituitary stalk (arrow). The abnormalities are non-discrete and radiologically inconsistent with a microadenoma or invasive macro adenoma of the pituitary gland. (b) Dedicated thin-section coronal contrast-enhanced T1-weighted image of the pituitary demonstrates the abnormal enhancement and thickening of the pituitary stalk as well as the cavernous sinus and pituitary parenchyma in more detail. (c) Dedicated thin-section sagittal contrast-enhanced T1-weighted image of the pituitary demonstrates the abnormal generalised thickening and enhancement of the pituitary stalk (arrow) consistent with granulomatous infundibulitis

She was treated with three pulses of i.v. methyl prednisolone 500 mg, with rapid improvement in her diplopia and normalization of the CRP. The right pupillary abnormality improved but the left pupil remained dilated (Fig. 5). Her oral prednisolone was increased to 60 mg, and she received three fortnightly doses of i.v. cyclophosphamide 750 mg (15 mg/kg) followed by three further doses at three-weekly intervals. Azathioprine was stopped. She also was given the second rituximab dose. She received topical mupirocin to reduce nasal Staphylococcus carriage and was started on oral co-trimoxazole both to reduce the risk of opportunistic infections and because this may reduce relapses in GPA [[10]]. Her swallowing remained compromised and she remained an inpatient for ongoing feeding via the nasogastric tube. Subsequently a percutaneous gastrostomy tube was inserted.Fig. 5

Photograph demonstrating dilated left pupil and nasal deformity. This was taken after 3 pulses of i.v. methyl prednisolone

Her admission was complicated by hypernatraemia with serum sodium rising to 157 mmol/L. She required 4–5 L of fluid per day to maintain her sodium level in the normal range. She had two episodes of syncope due to postural hypotension. Her fluid balance chart revealed polyuria. Blood glucose and calcium were normal. Repeat dedicated pituitary MRI showed pathological enhancement and diffuse thickening of the pituitary (Fig. 4 b&c). She was diagnosed with cranial diabetes insipidus and treated with desmopressin, with normalization of her serum sodium. She was discharged home with feeding via the gastrostomy tube.

After six pulses of cyclophosphamide, she showed marked clinical improvement. Her diplopia had resolved and eye movements had returned to normal. She was able to eat and drink normally. Her right-sided third nerve palsy had entirely resolved. Her left pupil remained dilated and reacted sluggishly to light, and a mild left facial weakness persisted. A further cranial MRI showed marked regression of the inflammatory changes in the skull base (Fig. 6). She was switched to maintenance therapy with azathioprine, and the prednisolone dose was slowly weaned to 5 mg daily. She remained clinically well on this treatment, with no progression of cranial disease on MRI, for 20 months following completion of cyclophosphamide. At this point, she had a relapse of ENT disease with nasal blockage and epistaxis requiring a tapering course of prednisolone 30 mg daily.Fig. 6

Axial intracranial contrast-enhanced T1-weighted MR image after six pulses of cyclophosphamide. There is reduction in the volume of abnormal cavernous sinus enhancing chronic inflammatory tissue (arrows) compared with pre-treatment imaging

Discussion

Our patient first presented with localised GPA confined to the nasopharynx and ear. Despite initial treatment with full-dose methotrexate and steroids, her disease progressed. She developed the unusual complications of extensive cranial nerve palsies (involvement of nerves II-IV, V3, and VI-XII) and diabetes insipidus due to granulomatous infiltration of the skull base.

Our report highlights several learning points. First, it demonstrates that localised GPA can be aggressive and result in serious morbidity. Assessment of disease severity is a key aspect of the management of AAV since it guides treatment decisions [[5], [6]]. Disease severity can be classified as life-threatening, organ-threatening (i.e. disease that will result in permanent tissue damage and/or loss of function unless appropriately treated), or non-organ threatening. Although our patient had anatomically localised cranial GPA, she developed organ-threatening disease with severe progressive cranial nerve involvement as a result of compression by inflammatory tissue. This included a vocal cord palsy, which resulted in dysphonia. If she had not been treated promptly, this could have become bilateral which can lead to life-threatening airway obstruction [[11]]. Glossopharyngeal, vagus and accessory nerve palsies resulted in severe dysphagia necessitating nasogastric feeding.

Second, this case illustrates central nervous system (CNS) manifestations of GPA, including the rare complication of cranial diabetes insipidus due to pituitary infiltration and compression. In contrast to peripheral nerve involvement, CNS disease in GPA is uncommon. In a European cohort of 128 GPA patients, 56 patients (44%) had peripheral neuropathy (either symmetrical polyneuropathy or mononeuritis multiplex), whilst only 9 patients (7%) had CNS involvement, of whom 6 had cranial nerve palsies [[12]]. CNS involvement occurred in 8% of cases in a cohort from the National Institutes of Health (NIH) [[13]], and cranial nerve palsies occurred in 21 of 324 patients (6%) attending the Mayo Clinic [[14]]. CNS disease in GPA is proposed to develop by three distinct but sometimes co-existing mechanisms [[15]]: by contiguous spread of granulomatous tissue from adjacent sites in the middle ear and sinuses (as in our patient), by primary granuloma formation within the CNS, or from vasculitis affecting the CNS. Seror et al. described three patterns of GPA-related CNS disease: chronic hypertrophic pachymeningitis, pituitary gland involvement, and cerebral vasculitis [[16]].

Yokoseki et al. reported a series of 36 patients with hypertrophic pachymengitis, of whom 17 had ANCA against MPO and 4 against PR3 [[17]]. Although the number of PR3 positive patients was small, this study found a higher frequency of pulmonary and renal disease in PR3 positive cases than in MPO+ cases, and that leptomeningeal and parenchymal involvement in the brain were more common in PR3 positive hypertrophic pachymeningitis compared with MPO positive and idiopathic hypertrophic pachymeningitis. In the presence of leptomengingeal AAV, cerebrospinal fluid analysis may reveal elevated protein and pleiocytosis, but these findings are non-specific. Other causes of hypertrophic pachymeningitis include other immune-mediated diseases (e.g. sarcoidosis and IgG4-related disease), infections, and neoplasms (particularly lymphoma) [[17]]. Lymphoma mimicking GPA with positive PR3 antibodies has been described [[18]]. However, in our patient, the radiological picture and the clinical course were not consistent with lymphoma.

Our patient had both chronic pachymeningitis and pituitary gland involvement, with meningeal thickening and pituitary infiltration evident on cranial imaging, and clinical and biochemical evidence of pituitary disease. Pituitary dysfunction due to GPA is rare, occurring in 9 of 819 patients (1.1%) in the French Vasculitis Study Group database [[19]], and 8 of 637 patients (1.3%) in a series from the Mayo Clinic [[20]]. We identified 58 previously reported cases of GPA with sellar involvement in the literature (Table 1), and analysed their clinical and demographic features. There was a significant female preponderance; 40 (69%) of the patients were female. Patients with pituitary involvement tended to be younger than GPA patients in general (median age at time of pituitary involvement 39.5 years, interquartile range 29–50 years). Pituitary involvement generally occurred early in the disease course. Of 46 cases where we were able to identify the age of onset of both GPA and pituitary involvement, in 28 (61%), pituitary disease was either the presenting feature or was diagnosed within a year of GPA onset. ENT involvement was the most common additional clinical GPA manifestation, occurring in 39 patients (67%). Other extra-CNS manifestations were, in order of decreasing frequency, pulmonary (n = 25), renal (n = 16), musculoskeletal (n = 15), ocular (n = 14), mucocutaneous (n = 12), peripheral neuropathy (n = 4), cardiac (n = 1), digital infarcts (n = 1), gastro-intestinal (n = 1). Diabetes insipidus was the most common endocrine abnormality, occurring in 47 patients (81%). In 4 of these, diabetes insipidus occurred following sellar surgery. Anterior pituitary hormone abnormalities occurred less frequently: hypogonadism was present in 32 patients, secondary hypothyroidism in 20, hyperprolactinaemia in 19, and growth hormone deficiency in 5. Reliable estimation of the frequency of adrenocorticotropic hormone (ACTH) deficiency was difficult due to therapeutic administration of exogenous corticosteroids in many cases. Typical MRI appearances include a sellar mass, sometimes with suprasellar extension, diffuse enlargement of the pituitary, thickening of the infundibulum (pituitary stalk), and enhancement with gadolinium contrast. Loss of the normal posterior pituitary hyperintensity on T1 weighted images was reported in 17 cases, and correlated with the presence of diabetes insipidus. In a few cases, hyperprolactinaemia and the presence of a pituitary lesion on imaging caused diagnostic confusion with a prolactinoma [[21], [22]]. However, diabetes insipidus and the loss of the normal high signal in the posterior pituitary on T1 weighted MRI are unusual in small pituitary adenomas. Our patient had diffuse pituitary and infundibular changes radiologically inconsistent with a pituitary adenoma.Table 1

Previous reports of sellar involvement in GPA

1st Author & year PMID No. of cases Age at GPA diagnosis Age at time of sellar involvement Sex Pituitary Imaging (MRI unless stated) Endocrinological abnormalities Non-CNS features ANCA
Haynes 1978 [[29]] 692550 1 26* 25 M NA DI Hyperprolactinaemia Normal TSHNormal LH & FSH Lung, renal N/A
Hurst 1983 [[30]] 6625709 1 47* 47 F CT normal DI Normal prolactin Normal TSHPost-menopausal LH/FSH Polyarthritis, ENT, ocular, mucocutaneous, pulmonary N/A
Lohr 1988 [[31]] 3172100 1 19* 19 F Intrasellar mass N/A ENT, pulmonary N/A
Rosete 1991 [[32]] 1865428 1 51* 51 F CT: pituitary enlargement DI N/A N/A
Czarnecki 1995 [[33]] 7611087 1 31 34 F Sellar mass with suprasellar extension. Enhancement of the stalk and hypothalamus. Loss of PS. DI Hyperprolactinaemia ENT, arthralgia N/A
Roberts 1995 [[34]] 7758239 2 71* 71 F Intrasellar mass with suprasellar extension DI (post-surgery)↓ TSH↓ LH & FSH↓ cortisolNormal prolactin None cANCA +ve
28* 28 F Intrasellar mass with low-density centre DI (post-surgery) Normal prolactin Normal TSHNormal LH & FSHNormal cortisol Ocular, arthralgia, cutaneous, renal cANCA +ve
Bertken 1997 [[35]] 9265867 1 36* 36 F Macrocystic pituitary mass with suprasellar extension. Hydrocephalus DI (post surgery) ↓ TSH response ↓ LH & FSH responses ENT, pulmonary, ocular ANCA -ve
Hajj-Ali 1999 [[36]] 10461488 1 N/A 21 F Normal DI N/A N/A
Katzman 1999 [[21]] 10219422 2 41* 41 F Pituitary enlargement. Loss of PS DI Hyperprolactinaemia Normal TSH Normal LH & FSH Constitutional, arthralgia, ENT, ocular, cutaneous cANCA +ve
18* 18 F Pituitary enlargement with contrast-enhancement.Loss of PS DIHyperprolactinaemiaNormal TSHNormal LH & FSH ENT, pulmonary cANCA +ve
Miesen 1999 [[37]] 10069203 1 46* 45 M Stalk thickening, contrast-enhancement.Loss of PS DIHyperprolactinaemiaHypogonadismNormal TSHNormal LH & FSHNormal cortisol & ACTH ENT, renal, pulmonary ANCA +ve
Goyal 2000 [[38]] 11003280 1 N/A (many years before pituitary involvement) 48 F Sellar mass with suprasellar extension. Contrast-enhancement DI↓ TSH Renal, pulmonary cANCA +ve
Tappouni 2000 [[39]] 11096156 1 58* 57 F Pituitary mass DI Constitutional, ENT, cutaneous, renal, pulmonary PR3 +ve
Woywodt 2000 [[40]] 11028850 1 30* 30 M N/A (diagnosed at autopsy) N/A N/A N/A
Garovic 2001 [[41]] 11136194 1 47* 47 F Cystic enlargement of the pituitary.Non-enhancing with gadolinium DI↓ prolactin↓ TSH↓ gonadotropins Constitutional, cutaneous, pulmonary cANCA +ve
Tao 2003 [[42]] 14642162 1 N/A 19 F Pituitary and stalk enlargement with heterogenous enhancement DI↓ TSHHypogonadism N/A N/A
Muir 2004 [[43]] 15150009 1 13* 13 M Diffuse pituitary enlargement.Foci of ↑ T1 signal. More extensive ↑ T2 signal. Central contrast-enhancement.Loss of PS. DI ENT, pulmonary ANCA +ve
Vittaz 2004 [[44]] 15687906 2 45 47 M Pituitary mass, with contrast-enhancement.Pituitary stalk thickened & infiltrated.Loss of PS Hyperprolactinaemia↓ testosterone↓ LH, normal FSH↓ cortisol & ACTHNormal TSH Constitutional, polyarthritis, peripheral neuropathy, pulmonary PR3 +ve
46 50 F Pituitary enlargement DIHyperprolactinaemiaHypogonadism Polyarthritis, ocular, mucocutaneous, ENT ANCA +ve
Duzgun 2005 [[45]] 15864593 1 47* 47 F Loss of PS DIAnterior pituitary hormones normal Polyarthritis, pulmonary, ENT, renal PR3 +ve
Seror 2006 [[16]] 16523054 3 45 50 F Nodular pituitary enlargement. Homogenous contrast-enhancement. Loss of PS DIHyperprolactinaemiaThyrotropic deficiencyHypogonadismCorticotropic deficiency ENT, ocular, mucocutaneous PR3 +ve
26 41 F Nodular pituitary enlargement. Contrast- enhancement DINormal anterior pituitary hormones ENT, arthralgia, ocular, renal PR3 +ve
55 57 M Pituitary enlargement & central necrosis. Heterogenous enhancement. DIHyperprolactinaemiaPanhypopituitarism Peripheral neuropathy, pulmonary, retinal vasculitis, digital, cerebral and renal infarcts PR3 +ve
Spisek 2006 [[46]] 16322901 1 30* 29 M Sellar cystic lesion DI↓ TSH↓ LH & FSH↓ ACTH↓ IGF-1 ENT PR3 +ve
McIntyre 2007 [[47]] 17318440 1 22* 22 F Heterogeneous enhancing pituitary mass DIHypogonadism Cutaneous, ocular, renal PR3 +ve
Thiryayi2007 [[48]] 17188492 1 21* 21 F Sellar mass with central hypo-intensity DI (post-surgery)Hypogonadism (post-surgery) Constitutional, arthralgia cANCA +ve
Yong 2008 [[49]] 17492510 1 33* 33 M Pituitary stalk thickening. Contrast-enhancing nodule at the superior aspectof the stalk.Loss of PS. DIHypogonadism↓ ACTHNormal prolactinNormal TSHNormal IGF-1 ENT PR3 +ve
Cunnington 2009 [[50]] 20107566 3 19 24 M Pituitary enlargement DIAnterior pituitary hormones normal Constitutional, ENT, pulmonary, ocular, cutaneous PR3 +ve
33 34 F Diffusely enlarged gland containing a poorly enhancing lesion with supra-sellar extension. Loss of PS. DINormal prolactinNormal TSH Constitutional, ENT cANCA+ve
26 35 M Diffusely enlarged pituitary and thickened stalk. DI↓ TSH Constitutional, ENT, pulmonary cANCA +ve
Xue 2009 [[51]] 19172275 1 63* 63 F Normal DITSH normalLH & FSH normal Constitutional, pulmonary, peripheral neuropathy PR3 +ve
Barlas 2011 [[52]] 21116602 1 35 37 F Anterior enlargement.Central area with low signal on T1 and high signal on T2. Post contrast enhancement of pituitary and stalk. Loss of PS. DIHyperprolactinaemia ENT, pulmonary, polyarthritis cANCA +ve
Santoro 2011 [[53]] 22147097 1 53* 53 F Hypointensity of adenohypophysis on T1.Hyperintense sectors on R side on T2.Peripheral contrast-enhancement.Stalk-thickening.Loss of PS. DI↓ TSHHypogonadismNormal prolactin Polyarthritis, cutaneous, pulmonary, renal cANCA +ve
Tenorio- Jimenez 2011 [[54]] 22673710 1 23 38 F MRI: marked infundibular thickening, sellar mass with hypointensity on T1. Loss of PS Hyperprolactinaemia↓ TSHHypogonadismPost pituitary hormones unaffected ENT, pulmonary, renal cANCA +ve (−ve by the time of sellar manifestations)
Hughes 2013 [[55]] 23186961 1 N/A 30 F Sellar mass Panhypopituitarism Ocular N/A
Pereira 2013 [[56]] 22898089 1 48* 48 F Appearances of pituitary microadenoma, but histopathlogy revealednecrotizinggranulomatousinflammation Hyperprolactinaemia↓ TSHPost pituitary hormones unaffected ENT N/A
Kapoor 2014 [[20]] 25077899 8 N/A 67 F Peripherally enhancing cystic sellar mass compressing the stalk HyperprolactinaemiaHypogonadismNormal TSH ENT, renal 7/8 cases PR3 +ve
N/A 48 F Multiple non-enhancing cystic areas in the pituitary, convexity of superior margin of pituitary DI↓ prolactin↓ TSHHypogonadismCorticotropic deficiency ENT, pulmonary, cutaneous
N/A 28 F Sellar mass with large zone of central non-enhancement and peripheral enhancement. Stalk displacement DIHypogonadismNormal prolactinNormal TSHNormal IGF-1Normal cortisol ENT, pulmonary, renal
N/A 55 M Sellar mass with suprasellar extension DIHypogonadismNormal prolactinNormal TSHNormal cortisolNormal IGF-1 ENT, pulmonary, renal, cutaneous, joints
N/A 35 M Necrotic sellar mass with peripheral enhancement & suprasellar extension. Thickened contrast-enhancing stalk DI↓ TSHHypogonadismNormal prolactinNormal cortisolNormal IGF-1 ENT
N/A 54 M Enlarged pituitary measuring 12 mm, with heterogeneous enhancement. Slight diffuse thickening of the stalk DI↓ TSHHypogonadismNormal prolactinNormal IGF-1 ENT, pulmonary, renal, cardiac
N/A 68 M Homogeneously enhancing sellar mass, extending into the cavernous sinus bilaterally. Stalk preserved. ↓ prolactin↓ TSHHypogonadism↓ IGF-1 ENT, joints
N/A 28 F Sellar mass extending into the suprasellar cistern, with low T2 signal in the periphery and a bright centre. Peripheral enhancement with central cystic change. Thickening of pituitary stalk DINormal prolactinNormal TSHNormal cortisolNormal IGF-1 ENT
De Parisot 2015 [[19]] 25906106 9 46* 46 F Enlarged posterior pituitary. Infiltration of posterior pituitary. Loss of PS DI ENT, ocular
60 70 M Normal ↓ TSHHypogonadism↓ IGF-1Normal prolactin ENT, peripheral neuropathy
23 24 F Enlarged pituitary. Irregularity of infundibulum. Heterogeneous enhancement of anterior pituitary. Loss of PS DI↓ TSHHypogonadismNormal prolactinNormal IGF-1 ENT
24* 24 M Enlarged infundibulum DIHyperprolactinaemia↓ TSHHypogonadismNormal IGF-1 Renal, ocular, joints, gastro-intestinal
66 77 M Enlarged pituitary. Stalk infiltration.Loss of PS. ↓ TSHHypogonadism↓ IGF-1Normal prolactin None
67 68 F Normal DIHyperprolactinaemiaNormal TSHNormal LH & FSHNormal IGF-1 ENT
28 42 F Heterogeneous enhancement of pituitary DIHyperprolactinaemiaHypogonadism↓ ACTH ENT, lung
55 57 M Sellar mass, heterogeneous.Enhancement. Enlargement and infiltration of stalk. Loss of PS DIHyperprolactinaemia↓ TSHHypogonadism↓ ACTH Pulmonary
46 50 F Enlargement and infiltration of pituitary. Heterogeneous enhancement, contact with optic chiasm DIHyperprolactinaemiaHypogonadismNormal TSHNormal IGF-1 ENT, ocular
Eli 2016 [[22]] 27521731 1 32* 29 F Homogenously enhancing sellar mass. Thickened stalk. Hyperprolactinaemia ENT, pulmonary MPO +ve
Esposito 2017 [[57]] 28540625 3 37* 37 F Sellar mass extending into the suprasellar cistern with peripheral enhancement and central cystic lesion. Stalk deviation. DIHypogonadismGH deficiency Constitutional, ENT PR3 +ve
36* 36 F Cystic pituitary mass DIAnterior pituitary function normal Constitutional, myalgia, ENT, pulmonary PR3 +ve
32* 32 F Sellar mass with homogeneous. Thickening of the pituitary stalk DIAnterior pituitary function normal ENT PR3 +ve

Abbreviations: ACTH adrenocorticotropic hormone, cANCA cytoplasmic pattern ANCA staining, DI diabetes insipidus, GH growth hormone, IGF-1 insulin-like growth factor 1, LH luteinising hormone, FSH follicular stimulating hormone, MPO myeloperoxidase, N/A data not available, PMID PubMed ID, PR3 proteinase-3, PS posterior signal.

*indicates cases where pituitary involvement was diagnosed prior to or at the time of GPA diagnosis

For the purposes of the Table, a TSH within the reference range but inappropriately low for the T4 has been included in the category “↓ TSH”

The third issue raised by this case is the wisdom of methotrexate treatment at the time of her initial presentation. The NORAM trial compared methotrexate with cyclophosphamide for the treatment of early, non-organ threatening systemic disease [[23]]. Whilst there was no significant difference in the primary endpoint of overall remission rates at 6 months, relapse rate at 18 months was higher in the methotrexate group, and there was delayed remission in the methotrexate group in patients with more extensive disease or pulmonary involvement. The lack of a difference between methotrexate and cyclophosphamide at 6 months might reflect the fact that patients in both treatment groups were still receiving steroids at this timepoint. Post-trial follow-up has revealed that patients in the methotrexate arm of the trial received more corticosteroids, cyclophosphamide, and other immunosuppressive agents than those in the cyclophosphamide group [[24]], indicating less effective disease control with methotrexate compared to cyclophosphamide induction therapy. In light of these data and our clinical experience, it is the authors’ personal view that methotrexate should be used for only the mildest cases of GPA, and we have a low threshold for switching to stronger immunosuppressive therapy in the face of active disease. This view is supported by the 2015 EULAR guidelines which reserve methotrexate for the treatment of non-organ threatening disease [[6]]. The EULAR guidelines specifically spell out that methotrexate is not suitable therapy for meningeal disease, or for nasal/paranasal disease with bony involvement, cartilage collapse or deafness, and thus do not support the use of methotrexate in this patient, even at the time of her initial presentation. The absence of pulmonary or renal disease and the perception that localised disease is benign may have contributed to her initial under-treatment, and the failure to escalate immunosuppression at her local hospital.

The final issue is the choice of rituximab versus cyclophosphamide. We initially opted for rituximab over cyclophosphamide to reduce the risk of infertility. However, in view of rapid clinical deterioration we commenced cyclophosphamide. The RAVE and RITUXIVAS studies both showed non-inferiority of rituximab compared to cyclophosphamide in AAV [[25], [26]]. However, the results from these trials cannot necessarily be extrapolated to our patient. In the RITUXIVAS trial all patients had glomerulonephritis. The RAVE study was not restricted to patients with renal involvement, but did not have any patients with cranial nerve palsies in the rituximab treatment arm. Nevertheless, case series suggest that rituximab can be effective in cranial GPA [[27], [28]]. It should be highlighted that rituximab has a relatively slow onset of action, and in retrospect our initial “bridging” steroid therapy (one pulse of 500 mg iv methyl prednisolone and 30 mg oral prednisolone) was insufficient. The patient improved markedly after we commenced high-dose corticosteroids and cyclophosphamide. For severe cases where rapid control of disease is necessary, this combination of cyclophosphamide and rituximab may be preferable to either drug alone. Indeed, in the RITUXIVAS trial i.v. cyclophosphamide 15 mg/kg was given alongside the rituximab doses in weeks 1 and 3 [[26]].

Conclusions

Pituitary involvement is a rare complication of GPA. It disproportionately affects female patients and tends to occur early in the disease course. Diabetes insipidus is the most commonly associated endocrinological abnormality. Our case report highlights that localised GPA is not necessarily indolent and that methotrexate may be inadequate treatment for localised disease. The presence of adverse features such as neurological involvement requires prompt recognition and aggressive therapy. Organ- or even life-threatening disease can occur in the absence of pulmonary or renal involvement. In this case a good outcome was achieved with high-dose steroid and dual treatment with cyclophosphamide and rituximab with minimal adverse events. In cases of severe neurological compromise due to GPA where a rapid therapeutic effect is required, such combination therapy may be a useful strategy. Finally, such cases should be managed by a multi-disciplinary team in a tertiary referral centre.

Acknowledgements

Acknowledgements

We thank Prof. David Jayne for his comments on the manuscript.

Funding

Dr. Peters was supported by a Career Development Award from the Cambridge British Heart Foundation Centre for Research Excellence (RE/13/6/30180) and a UK Research Institutes Innovation Fellowship at HDR UK (MR/S004068/1).

References

  1. JC JennetteRJ FalkPA BaconN BasuMC CidF Ferrario2012 revised international Chapel Hill consensus conference nomenclature of VasculitidesArthritis Rheum201365111110.1002/art.3771523045170
  2. GC GodmanJ ChurgWegener's granulomatosis: pathology and review of the literatureAMA Arch Pathol195458653355313217569
  3. AS FauciSM WolffWegener's granulomatosis: studies in eighteen patients and a review of the literatureMedicine (Baltimore)197352653556110.1097/00005792-197311000-000024748591
  4. EW WaltonGiant-cell granuloma of the respiratory tract (Wegener's granulomatosis)Br Med J19582509126527010.1136/bmj.2.5091.26513560836
  5. E NtatsakiD CarruthersK ChakravartyD D'CruzL HarperD JayneBSR and BHPR guideline for the management of adults with ANCA-associated vasculitisRheumatology (Oxford)201453122306230910.1093/rheumatology/ket44524729399
  6. M YatesRA WattsIM BajemaMC CidB CrestaniT HauserEULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitisAnn Rheum Dis20167591583159410.1136/annrheumdis-2016-20913327338776
  7. CB CarringtonA LiebowLimited forms of angiitis and granulomatosis of Wegener's typeAm J Med196641449752710.1016/0002-9343(66)90214-25923596
  8. JH StoneWegener's Granulomatosis Etanercept Trial Research GLimited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trialArthritis Rheum20034882299230910.1002/art.1107512905485
  9. JE PetersAD SalamaPW IndWegener's granulomatosis presenting as acute systemic vasculitis following 20 years of limited tracheobronchial diseaseJ Laryngol Otol2009123121375137710.1017/S002221510900454X19175952
  10. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener study group. N Engl J Med. 1996;335(1):16–20.
  11. JE PetersCJ BurkeVH MorrisThree cases of rheumatoid arthritis with laryngeal stridorClin Rheumatol201130572372710.1007/s10067-010-1657-221213004
  12. K de GrootDK SchmidtAC ArltWL GrossE Reinhold-KellerStandardized neurologic evaluations of 128 patients with Wegener granulomatosisArch Neurol20015881215122110.1001/archneur.58.8.121511493161
  13. GS HoffmanGS KerrRY LeavittCW HallahanRS LebovicsWD TravisWegener granulomatosis: an analysis of 158 patientsAnn Intern Med1992116648849810.7326/0003-4819-116-6-4881739240
  14. H NishinoFA RubinoRA DeRemeeJW SwansonJE ParisiNeurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo ClinicAnn Neurol19933314910.1002/ana.4103301038388187
  15. DA DrachmanNeurological complications of Wegener's granulomatosisArch Neurol19638214515510.1001/archneur.1963.00460020045003
  16. R SerorA MahrJ RamanoelinaC PagnouxP CohenL GuillevinCentral nervous system involvement in Wegener granulomatosisMedicine (Baltimore)2006851546510.1097/01.md.0000200166.90373.4116523054
  17. A YokosekiE SajiM ArakawaT KosakaM HokariY ToyoshimaHypertrophic pachymeningitis: significance of myeloperoxidase anti-neutrophil cytoplasmic antibodyBrain2014137Pt 252053610.1093/brain/awt31424271323
  18. Shinkawa Y, Hatachi S, Yagita M. Intravascular large B-cell lymphoma with a high titer of proteinase-3-anti-neutrophil cytoplasmic antibody mimicking granulomatosis with polyangiitis. Mod Rheumatol. 2016:1–3.
  19. A De ParisotX PuechalC LangrandG RaverotH GilL PerardPituitary involvement in granulomatosis with polyangiitis: report of 9 patients and review of the literatureMedicine (Baltimore)20159416e74810.1097/MD.000000000000074825906106
  20. E KapoorR Cartin-CebaU SpecksJ LeavittB EricksonD EricksonPituitary dysfunction in granulomatosis with polyangiitis: the Mayo Clinic experienceJ Clin Endocrinol Metab201499113988399410.1210/jc.2014-196225077899
  21. GL KatzmanCA LangfordMC SnellerM KobyNJ PatronasPituitary involvement by Wegener's granulomatosis: a report of two casesAJNR Am J Neuroradiol199920351952310219422
  22. IM EliA RahejaHJ CornDL SimmonsCA PalmerWT CouldwellSellar Wegener granulomatosis masquerading as Cabergoline-resistant ProlactinomaWorld Neurosurg20169562210.1016/j.wneu.2016.07.10827521731
  23. K De GrootN RasmussenPA BaconJW TervaertC FeigheryG GregoriniRandomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitisArthritis Rheum20055282461246910.1002/art.2114216052573
  24. M FaurschouK WestmanN RasmussenK de GrootO FlossmannP HoglundBrief report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitisArthritis Rheum201264103472347710.1002/art.3454722614882
  25. JH StonePA MerkelR SpieraP SeoCA LangfordGS HoffmanRituximab versus cyclophosphamide for ANCA-associated vasculitisN Engl J Med2010363322123210.1056/NEJMoa090990520647199
  26. RB JonesJW TervaertT HauserR LuqmaniMD MorganCA PehRituximab versus cyclophosphamide in ANCA-associated renal vasculitisN Engl J Med2010363321122010.1056/NEJMoa090916920647198
  27. M Martinez Del PeroA ChaudhryRB JonesP SivasothyP JaniD JayneB-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort studyClin Otolaryngol200934432833510.1111/j.1749-4486.2009.01968.x19673980
  28. MJ GuerryP BroganIN BruceDP D'CruzL HarperR LuqmaniRecommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitisRheumatology (Oxford)201251463464310.1093/rheumatology/ker15021613248
  29. BF HaynesAS FauciDiabetes insipidus associated with Wegener's granulomatosis successfully treated with cyclophosphamideN Engl J Med19782991476410.1056/NEJM197810052991406692550
  30. NP HurstNA DunnTM ChalmersWegener's granulomatosis complicated by diabetes insipidusAnn Rheum Dis198342560060110.1136/ard.42.5.6006625709
  31. KM LohrLM RyanRJ ToohillT AndersonAnterior pituitary involvement in Wegener's granulomatosisJ Rheumatol19881558558573172100
  32. A RoseteAR CabralA KrausD Alarcon-SegoviaDiabetes insipidus secondary to Wegener's granulomatosis: report and review of the literatureJ Rheumatol19911857617651865428
  33. EJ CzarneckiEM SpicklerMR demonstration of Wegener granulomatosis of the infundibulum, a cause of diabetes insipidusAJNR Am J Neuroradiol1995164 Suppl9689707611087
  34. GA RobertsE ErenH SinclairM PellingA BurnsR BradfordTwo cases of Wegener's granulomatosis involving the pituitaryClin Endocrinol199542332332810.1111/j.1365-2265.1995.tb01882.x
  35. RD BertkenVR CooperWegener granulomatosis causing sellar mass, hydrocephalus, and global pituitary failureWest J Med1997167144479265867
  36. RA Hajj-AliIW UthmanIA SaltiGS ZaatariMC HaddadFW NasrWegener's granulomatosis and diabetes insipidusRheumatology (Oxford)199938768468510.1093/rheumatology/38.7.68410461488
  37. WM MiesenEN JanssensEF van BommelDiabetes insipidus as the presenting symptom of Wegener's granulomatosisNephrol Dial Transplant199914242642910.1093/ndt/14.2.42610069203
  38. M GoyalW KucharczykE KeystoneGranulomatous hypophysitis due to Wegener's granulomatosisAJNR Am J Neuroradiol20002181466146911003280
  39. R TappouniA BurnsPituitary involvement in Wegener's granulomatosisNephrol Dial Transplant200015122057205810.1093/ndt/15.12.205711096156
  40. A WoywodtH KnoblauchR KettritzW SchneiderU GobelSudden death and Wegener's granulomatosis of the pituitaryScand J Rheumatol200029426426610.1080/03009740075004143311028850
  41. VD GarovicBL ClarkeTS ChilsonU SpecksDiabetes insipidus and anterior pituitary insufficiency as presenting features of Wegener's granulomatosisAm J Kidney Dis2001371E510.1016/S0272-6386(01)90002-211136194
  42. J TaoY DongPituitary involvement in Wegener's granulomatosis: a case report and review of the literatureChin Med J2003116111785178814642162
  43. BM MuirRL HulettJG ZornWegener's granulomatosis complicated by central diabetes insipidus in a pediatric patientAJR Am J Roentgenol200418261560156210.2214/ajr.182.6.182156015150009
  44. L VittazJ RamanoelinaA MahrR CohenP CohenG ReachPituitary involvement in Wegener's granulomatosis. Two casesPresse Med200433221585159010.1016/S0755-4982(04)98998-115687906
  45. N DuzgunY MorrisS GulluA GursoyA EnsariOO KumbasarDiabetes insipidus presentation before renal and pulmonary features in a patient with Wegener's granulomatosisRheumatol Int2005261808210.1007/s00296-005-0583-015864593
  46. R SpisekE KolouchovaJ JensovskyR RusinaP FendrychJ PlasCombined CNS and pituitary involvement as a primary manifestation of Wegener granulomatosisClin Rheumatol200625573974210.1007/s10067-005-0065-516322901
  47. EA McIntyreP PerrosFatal inflammatory hypophysitisPituitary200710110711110.1007/s11102-007-0016-z17318440
  48. W ThiryayiMH DonaldsonD BorderA TyagiAn enhancing pituitary lesion in a young woman: a diagnostic dilemmaJ Clin Neurosci200714328628810.1016/j.jocn.2005.12.00517188492
  49. TY YongJY LiL AmatoK MahadevanPJ PhillipsPS CoatesPituitary involvement in Wegener's granulomatosisPituitary2008111778410.1007/s11102-007-0021-217492510
  50. JR CunningtonR JoisI ZammitD ScottJ IsaacsDiabetes insipidus as a complication of Wegener's granulomatosis and its treatment with biologic agentsInt J Rheumatol2009200934613610.1155/2009/34613620107566
  51. J XueH WangH WuQ JinWegener's granulomatosis complicated by central diabetes insipidus and peripheral neutrophy with normal pituitary in a patientRheumatol Int200929101213121710.1007/s00296-008-0774-619172275
  52. NB BarlasHH HassanFB Al BadrA BilalStructural and functional involvement of pituitary gland in Wegener's granulomatosisClin Neuroradiol2011211313310.1007/s00062-010-0037-221116602
  53. SG SantoroAH GuidaAE FuriosoP GlikmanAS RogozinskiPanhypopituitarism due to Wegener's granulomatosisArq Bras Endocrinol Metabol201155748148510.1590/S0004-2730201100070000822147097
  54. Tenorio Jimenez C, Montalvo Valdivieso A, Lopez Gallardo G, McGowan B. Pituitary involvement in Wegener's granulomatosis: unusual biochemical findings and severe malnutrition. BMJ Case Rep. 2011;2011
  55. J HughesG BarkhoudarianP CiarliniER LawsE ModySE InzucchiRefractory pituitary granulomatosis with polyangiitis (Wegener's) treated with rituximabEndocr Pract2013191e1e710.4158/EP12181.CR23186961
  56. EA PereiraP PlahaM HoferN KaravitakiSA CudlipHypophyseal Wegener's granulomatosis presenting by visual field constriction without hypopituitarismClin Neurol Neurosurg2013115676276410.1016/j.clineuro.2012.06.04122898089
  57. D EspositoP TrimpouD GiuglianoM DehlinO RagnarssonPituitary dysfunction in granulomatosis with polyangiitisPituitary201720559460110.1007/s11102-017-0811-028540625
The underlying source XML for this text is taken from https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5930853/fullTextXML. The license for the article is Creative Commons Attribution 4.0 International. The main subject has been identified as neurohypophyseal diabetes insipidus.